| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 08/01/2002 | WO2002059112A2 Pyrazole compounds useful as protein kinase inhibitors |
| 08/01/2002 | WO2002059111A2 Pyrazole compounds useful as protein kinase inhibitors |
| 08/01/2002 | WO2002059110A1 Pyrimidineamines as angiogenesis modulators |
| 08/01/2002 | WO2002059106A1 Isoindole-imide compounds, compositions, and uses thereof |
| 08/01/2002 | WO2002059102A2 Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and use |
| 08/01/2002 | WO2002059098A1 Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors |
| 08/01/2002 | WO2002059092A1 Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof |
| 08/01/2002 | WO2002059088A1 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| 08/01/2002 | WO2002059083A2 Novel compounds |
| 08/01/2002 | WO2002059080A2 Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| 08/01/2002 | WO2002058793A1 Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy |
| 08/01/2002 | WO2002058789A1 Ocular iontophoretic device and method of use |
| 08/01/2002 | WO2002058775A2 Device for dilating and irradiating a vascular segment or body passageway |
| 08/01/2002 | WO2002058734A2 Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions |
| 08/01/2002 | WO2002058733A2 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| 08/01/2002 | WO2002058732A2 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| 08/01/2002 | WO2002058731A2 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 08/01/2002 | WO2002058730A2 Compositions for treatment of ocular neovascularization |
| 08/01/2002 | WO2002058720A2 Angiogenically effective unit dose of fgf-2 and method of use |
| 08/01/2002 | WO2002058718A2 Use of compositions containing pdgf-bb for promoting angiogenesis |
| 08/01/2002 | WO2002058706A2 Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy |
| 08/01/2002 | WO2002058704A1 Imidazolyl derivatives as corticotropin releasing factor inhibitors |
| 08/01/2002 | WO2002058703A2 The treatment of sexual dysfunction and cardiovascular disease with quinolinone enantiomers |
| 08/01/2002 | WO2002058702A1 Urotensin-ii receptor antagonists |
| 08/01/2002 | WO2002058698A2 Malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| 08/01/2002 | WO2002058696A2 The use of substituted azetidinone compounds for the treatment of sitosterolemia |
| 08/01/2002 | WO2002058690A2 Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors |
| 08/01/2002 | WO2002058685A2 Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications |
| 08/01/2002 | WO2002058683A2 Carotenoids as anti-hypertension agents |
| 08/01/2002 | WO2002058682A2 An anti-atherosclerosis composition containing carotenoids and method for inhibiting ldl oxidation |
| 08/01/2002 | WO2002058679A2 Antiangiogenic compounds and an assay for inhibitors of cell invasion |
| 08/01/2002 | WO2002058677A1 New film coating |
| 08/01/2002 | WO2002058626A2 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 08/01/2002 | WO2002058625A2 Herbal composition for angina pectoris, method to prepare same and uses thereof |
| 08/01/2002 | WO2002042278A3 Imidazole and benzimidazole caspase inhibitors and uses thereof |
| 08/01/2002 | WO2002040461A3 Aminoalkoxybiphenyl carboxamides as histamine-3 receptor ligands and their therapeutic applications |
| 08/01/2002 | WO2002040048A3 Recombined anti-gpiib/iiia antibodies used for inhibiting angiogenesis |
| 08/01/2002 | WO2002026733A3 sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES |
| 08/01/2002 | WO2002022572A3 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| 08/01/2002 | WO2002022166A3 Tweak receptor agonists as anti-angiogenic agents |
| 08/01/2002 | WO2002016620A3 Modulation of stem cell differentiation |
| 08/01/2002 | WO2002014319A3 Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| 08/01/2002 | WO2002012227A3 Indole, azaindole and indazole derivatives having vegf inhibiting activity |
| 08/01/2002 | WO2002012190A3 Non-imidazole aryloxypiperidines as h3 receptor ligands |
| 08/01/2002 | WO2002011766A3 Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation |
| 08/01/2002 | WO2002008285A3 Il-17 molecules and uses thereof |
| 08/01/2002 | WO2002005794A3 Use of fluorescein derivatives for the treatment of diseases responsive to the activation of the cystic fibrosis transmembrane conductance regulator chloride channel |
| 08/01/2002 | WO2002002625A3 Novel fibroblast growth factors and nucleic acids encoding same |
| 08/01/2002 | WO2002002505A3 Compounds to treat alzheimer's disease |
| 08/01/2002 | WO2001098367A3 Neuroactive peptides for treatment of hypoxia and related conditions |
| 08/01/2002 | WO2001098279A3 Bis-arylsulfones |
| 08/01/2002 | WO2001096565A3 Binding agents: chimeric ligand/receptor proteins |
| 08/01/2002 | WO2001091587A3 Oil compositions comprising short, medium and long chain triglycerides and use thereof in reducing weight gain |
| 08/01/2002 | WO2001090315A3 Production of neurons from stem cells |
| 08/01/2002 | WO2001089538A3 Apoptotic entities for use in treatment of endothelium dysfunction disorders |
| 08/01/2002 | WO2001089536A3 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders |
| 08/01/2002 | WO2001083554A3 Anti-inflammatory compounds and uses thereof |
| 08/01/2002 | WO2001082953A3 Methods for treatment of diseases associated with inflammation under non-ischemic conditions |
| 08/01/2002 | WO2001072836A3 G-protein coupled receptors |
| 08/01/2002 | WO2001072335A3 Methods for effecting neuroprotection using a potassium channel modulator |
| 08/01/2002 | WO2001070738A3 Tri-aryl-substituted-ethane pde4 inhibitors |
| 08/01/2002 | WO2001041754A9 Inhibitors of collagen-induced platelet aggregation |
| 08/01/2002 | WO2001012206A3 Soy-glycine extracts and aromatase inhibitors for positively influencing collagen |
| 08/01/2002 | US20020103376 Dithiepino[6,5-b]pyridines, and related compositions and methods |
| 08/01/2002 | US20020103373 Tricyclic benzodiazepines as vasopressin receptor antagonists |
| 08/01/2002 | US20020103345 Bispecific immunoglobulin-like antigen binding proteins and method of production |
| 08/01/2002 | US20020103259 Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| 08/01/2002 | US20020103247 Indole and dihydroindole derivatives |
| 08/01/2002 | US20020103245 1-aryl or heteroaryl substituted 5-amino-4 carbonylpyrazole derivatives; antiinflammatory agents |
| 08/01/2002 | US20020103242 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| 08/01/2002 | US20020103239 Such as N-hydroxy-2-(((4-phenoxyphenyl)-sulfonyl)methyl) benzamide which inhibits matrix metalloprotease activity |
| 08/01/2002 | US20020103235 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists |
| 08/01/2002 | US20020103230 Heterocyclic compounds |
| 08/01/2002 | US20020103229 Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| 08/01/2002 | US20020103227 Nitric oxide synthase inhibitors such as 6(4'-(4-phenethyl-piperazin-1-ylmethyl)-biphenyl-4-yl)-pyridin-2-ylamine for treatment and prevention of central nervous system disorders |
| 08/01/2002 | US20020103225 Comprises solid amorphous dispersion of compounds such as (2R,4S)4-((3,5-dichloro-benzyl)-methoxycarbonyl-amino)-6,7-dimethoxy-2 -methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester for elevating plasma lipid levels |
| 08/01/2002 | US20020103221 Such as 2-amino-N-(2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo -(4,3-c)pyridin-5-yl)-1-(R)-benzyloxymethyl- 2-oxo-ethyl)-isobutyramide or prodrug thereof; for improving functional health of elderly/isolated |
| 08/01/2002 | US20020103213 Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis |
| 08/01/2002 | US20020103209 Serotonergic modulators; for treatment of disorders of the central nervous system including psychotic disorders, hypertension and vascular disorders, migraine |
| 08/01/2002 | US20020103198 Acylamino cyclopropane derivatives |
| 08/01/2002 | US20020103190 Azo amino acids derivatives |
| 08/01/2002 | US20020103182 Improving elasticity or reducing wrinkles of a skin, for example; advanced glycosylation endproducts" or AGEs |
| 08/01/2002 | US20020103178 Administering steriods (e.g. estrogens), wherein a non-fused polycyclic, hydrophobic substituent such as adamantanyl is attached to the hydroxy-substituted A-ring thereof |
| 08/01/2002 | US20020103172 Vitamin d3 derivatives |
| 08/01/2002 | US20020103167 Method of treating certain eye diseases |
| 08/01/2002 | US20020103158 Dinucleoside polyphosphates which facilitate secretory mechanisms, i.e. increasing the hydration of mucus secretions, stimulating the production of mucins and increasing ciliary beat frequency to facilitate clearance |
| 08/01/2002 | US20020103141 DNA topoisomerase I and cyclooxygenase-2 (COX-2) inhibiting agents |
| 08/01/2002 | US20020103123 Administering coumpounds such as aromatic alkyl diamine derivatives as Y5 receptor agonist or antagonist to increase or decrease food consumption |
| 08/01/2002 | US20020102710 Polypeptide for use in the treatment of cancer, autoimmune diseases and inflammation |
| 08/01/2002 | US20020102707 Nucleotide sequences coding polypeptide for use in the treatment of sexual disorders |
| 08/01/2002 | US20020102691 Enzymatic polypeptide for use in treatment and prevention of, heart liver and inflammatory disorders |
| 08/01/2002 | US20020102645 Novel member of the lysyl oxidase gene family |
| 08/01/2002 | US20020102642 Nuclelotide sequences coding preferential protein for use in therapeutic, diagnostic and medical imaging |
| 08/01/2002 | US20020102603 Compositions and methods for the treatment and diagnosis of cardiovascular disease |
| 08/01/2002 | US20020102535 Nucleic acid molecules and polypeptides for immune modulation |
| 08/01/2002 | US20020102307 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| 08/01/2002 | US20020102294 Aerosols comprising nanoparticle drugs |
| 08/01/2002 | US20020100854 Furnace mount and method of installation |
| 08/01/2002 | US20020100185 Drying method for selectively removing volatile components from wet coatings |
| 08/01/2002 | DE10103647A1 Verfahren zur Herstellung eines Pyrazolo (4,3-d) pyrimidinderivates A process for preparing a pyrazolo (4,3-d) pyrimidine derivative |